Overview
This randomized clinical trial studies how well high volume washing of the abdomen works in increasing survival after surgery in patients with pancreatic cancer that can be removed by surgery. High volume washings may remove free floating cancers present after surgery and help prolong survival in patients with pancreatic cancer.
Description
PRIMARY OBJECTIVES:
I. Overall survival (OS) (18 to 27 months after resection).
SECONDARY OBJECTIVES:
I. Disease free survival (DFS). II. Complication rate. III. Site of first-recurrence (by site, and distant vs. local). IV. Clearance of malignant cells pre vs. post-lavage.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I (EIPL-S): Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy. Immediately after removal of tumor, patients receive extensive intraoperative peritoneal saline (EIPL-S) lavage 10 times over 15 minutes.
ARM II (EIPL-D): Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy. Immediately after removal of tumor, patients receive extensive intraoperative peritoneal distilled water (EIPL-D) lavage 10 times over 15 minutes.
ARM III (NO LAVAGE): Patients undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy with no extensive lavage after removal of tumor.
After completion of study treatment, patients are followed up every 3 months.
Eligibility
Inclusion Criteria:
- The subject has a surgical indication for pancreatectomy (pancreaticoduodenectomy, distal pancreatectomy, total pancreatectomy)
- A diagnosis of pancreatic or other periampullary cancer is suspected preoperatively
- In the opinion of the surgeon, the subject has no medical contraindications to pancreatectomy
- The subject is willing to consent to randomization of lavage vs. standard lavage
Exclusion Criteria:
- The subject does not have a surgical indication for pancreatectomy
- In the opinion of the surgeon, the subject has medical contraindications to pancreatectomy
- Age < 18 years of age
- The subject is not willing to consent to EIPL-S lavage vs. EIPL-D lavage vs. standard
- Known benign or indolent disease, including benign pancreatic cystic tumors or pancreatic endocrine tumors
- Other malignancy within five years, unless the probability of recurrence of the prior malignancy is < 5% as determined by the principal investigator based on available information; patient's curatively treated for squamous and basal cell carcinoma of the skin or patients with a history of malignant tumor in the past that have been disease free for at least five years are also eligible for this study
- Evidence of metastatic disease